Joe has covered a wide range of biopharmaceutical stories since 2007 and contributes to Scrip, In Vivo, Pink Sheet and related Citeline publications. His specialties include business development, commercial strategies and liver and infectious diseases.
Latest from Joseph Haas
Dalzanemdor missed its primary endpoint in a Phase II Parkinson’s study, Sage announced, following April’s Phase II miss in Alzheimer’s. Phase II data in Huntington’s are still expected this year.
Plus deals involving AbbVie/Ripple, Novo Nordisk/Korro Bio, Novo Nordisk/NanoVation, Bharat, Alopexx, Gilead/Genesis, Lilly/Genetic Leap, Proveca/Cessatech, Vivtex/Equillium and more.
Deal Snapshot: The Belgian company follows a tradition of Western pharma companies relying on local expertise to market their products in China.
While 2024 has seen two buyouts of antibody-drug conjugate specialists with $1bn-plus price tags, the focus on ADCs has continued, accounting for almost half of recent oncology deals.
Plus deals involving Lilly/Oblique, Rafael Holdings/Cyclo, ADCendo/Multitude, Ocuvex/Visiox and more.
ARS will compete directly with EpiPen and other injectable products with inhaled neffy as the first needle-free epinephrine therapy for severe allergy attacks. EU approval is thought imminent.